第 1 頁 共 10 頁 v 1.1.1 FF301 | 證券代號 (如上市) | 06855 | 說明 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000 | USD | | 0.0001 USD | | 50,000 | | 增加 / 減少 (-) | | | | 0 | | USD | | 0 | | 本月底結存 | | | 500,000,000 | USD | | 0.0001 USD | | 50,000 | 本月底法定/註冊股本總額： USD 50,000 FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2025年8月31日 | | | | 狀態: 新提交 | | --- | --- | --- | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | | | | 公司名稱: | 亞 ...

Group 1 - The A-share market is experiencing a correction, particularly in the pharmaceutical sector, with leading innovative drug companies like Huadong Medicine and BeiGene dropping over 5% [1] - The Hong Kong market's innovative drug ETF (520880) saw a significant decline of 3.32% after a previous rally, indicating a volatile trading environment [1][3] - The innovative drug ETF (520880) has accumulated over 6.2 billion yuan in net inflows over the past 60 days, reflecting strong investor interest despite recent market fluctuations [3][5] Group 2 - Upcoming major conferences, such as the World Lung Cancer Conference, are expected to catalyze a rebound in the innovative drug sector, with companies like CanSino Biologics and BeiGene presenting new research [5] - The innovative drug sector is anticipated to benefit from global competitiveness, overseas expansion, and supportive policies, which are expected to reshape valuations [5] - The Hong Kong innovative drug ETF (520880) is set to revise its index to focus solely on innovative drug research companies, enhancing its purity and potential performance [6] Group 3 - The innovative drug ETF (520880) has shown a remarkable year-to-date increase of 118.95%, outperforming other indices in the sector [8] - The medical ETF market is currently valued at 271.33 billion yuan, making it the largest in the pharmaceutical and medical category [10]

Group 1 - The launch of the Hong Kong and US stock performance meeting roadshow channel by Panorama Network provides a new platform for Chinese companies to communicate with global investors, enhancing the globalization of Chinese enterprises [1][4] - The China Securities Regulatory Commission has introduced five measures to support leading domestic companies in listing and financing in Hong Kong, significantly boosting the activity of the Hong Kong market as a bridge for mainland enterprises to "go global" [2][3] - The Hang Seng Index has shown a year-to-date increase of 27.10% as of September 2, 2025, indicating enhanced market confidence and sustained capital inflow [2] Group 2 - The IPO market in Hong Kong has performed exceptionally well, with total fundraising reaching 138.275 billion HKD as of September 2, 2025, surpassing the total for the entire year of 2024 [2][3] - Notable companies such as CATL and Heng Rui Pharmaceutical have emphasized internationalization as a strategic focus, with CATL planning to allocate approximately 90% of its raised funds for projects in Hungary [3] - The US stock market has shown steady performance, with the Nasdaq index increasing by 10.20% year-to-date as of September 2, 2025, driven by the technology sector [3] Group 3 - The Panorama Network's new channel allows investors to access real-time performance explanations, strategic interpretations, and major updates from Chinese companies listed overseas, thereby reducing information asymmetry and improving decision-making quality [4][6] - Since 2017, the Hong Kong Stock Exchange has utilized Panorama Network for live broadcasts of annual and interim performance meetings, completing 12 roadshows to date [4] - The Panorama Network has established a strong market presence, with over 3,500 listed companies on its service platform, achieving a market coverage rate of 66% [5]

Group 1 - The Hong Kong stock market for innovative drugs opened high but fell, with Zai Lab leading the decline by over 13% and other companies like Innovent Biologics and Ascentage Pharma dropping over 5% [1] - The Hong Kong Stock Connect Innovative Drug ETF (520880) experienced a significant drop of over 4%, with a trading volume of nearly 350 million yuan [1] - The ETF had previously seen four consecutive days of gains, reaching a new closing high [1] Group 2 - The World Lung Cancer Conference (WCLC) will take place from September 6 to 9 in Barcelona, Spain, where Chinese pharmaceutical companies will showcase innovative drug results [3] - Companies such as CanSino Biologics, BeiGene, and Baillie Gifford will present their latest research during the conference [3] - The upcoming conferences and the peak season for licensing agreements with multinational pharmaceutical companies (MNCs) are expected to create a favorable environment for innovative drugs in the coming quarter [3] Group 3 - The Hong Kong Stock Connect Innovative Drug ETF (520880) has shown strong performance, with a year-to-date increase of 118.95%, leading among various innovative drug indices [3][4] - The ETF is set to revise its index compilation rules to exclude companies primarily engaged in CXO services, focusing solely on innovative drug research and development [5] - This revision is expected to enhance the ETF's performance during the upward cycle of the innovative drug industry [5]

Group 1 - The Hong Kong innovative drug sector is experiencing strong performance, with the Guozheng Hong Kong Stock Connect Innovative Drug Index rising nearly 2%, approaching the previous high point from August 19 [1] - The Hong Kong Innovative Drug ETF (159567) has seen a cumulative increase of over 110% this year, making it one of the six ETFs in the market that have doubled in value [1] - The ETF has recorded positive growth in fund shares for seven consecutive months from February to August, with circulating shares increasing more than 17 times [1] Group 2 - China’s innovative drug companies are well-positioned for global competition, supported by over a decade of rapid development in the sector [1] - The purchasing behavior of overseas multinational corporations (MNCs) has validated the innovative research and development capabilities of domestic companies, particularly in the oncology and respiratory fields [1] - The Hong Kong Innovative Drug ETF primarily tracks the Guozheng Hong Kong Stock Connect Innovative Drug Index, focusing on biopharmaceuticals and chemical pharmaceuticals, with 9 out of the top 10 constituent stocks being biotech companies involved in core innovative drug technologies [1]

Group 1 - The core viewpoint emphasizes the acceleration of the development of China's biopharmaceutical industry, focusing on innovation-driven, long-cycle, and differentiated development to establish a national team in the biopharmaceutical sector [1] - In the first half of 2025, the number of approved innovative drugs in China reached 43, a year-on-year increase of 59%, with domestic innovative drugs accounting for 93% [1] - A complete policy support system has been established since 2021, facilitating the entire process from research and development to market access, clinical trials, payment, and insurance for innovative drugs [2] Group 2 - The total transaction amount for overseas licensing by Chinese pharmaceutical companies reached $51.9 billion in 2024, a 36% increase from the previous year, with the amount exceeding $60.8 billion in the first half of 2025 [2] - The collaboration between 3SBio and Pfizer for a PD-1/VEGF bispecific antibody set a record for the highest upfront payment of $1.25 billion for domestic innovative drug licensing [3] - The partnership between Heng Rui Medicine and GlaxoSmithKline has a potential total value of $12 billion, showcasing the enhanced global competitiveness of Chinese innovative drugs [3] Group 3 - The State-owned Assets Supervision and Administration Commission encourages state-owned enterprises to enhance their influence in the biopharmaceutical sector through mergers, acquisitions, and investments [4] - Domestic pharmaceutical companies are shifting from being technology followers to key contributors in global innovation, with significant advancements in various therapeutic areas [4] - Morgan Stanley predicts that by 2030, innovative drug sales will account for 53% of China's pharmaceutical market, up from 29% in 2023, with a compound annual growth rate of 21% [5]

Core Viewpoint - The enthusiasm for innovative drug companies entering the Hong Kong stock market continues, with Ying Shi Biotech being a recent applicant focusing on cancer drug development [1] Company Overview - Ying Shi Biotech was founded in 2017 and specializes in the research and development of new cancer drugs, led by founder Wang Zaiqi, who has extensive experience in multinational pharmaceutical companies [1][2] - The company has completed six rounds of financing totaling $130 million, with a post-C round valuation of $306 million [1] Market Context - In 2023, Ying Shi Biotech began preparations for its IPO, but faced challenges due to policy changes affecting unprofitable biotech companies in China [2] - The market has since recovered, with 60 healthcare companies applying for listing on the Hong Kong Stock Exchange, over 50% of which are innovative drug companies [2] Product Focus - Ying Shi Biotech is developing Ifebemtinib, a FAK (Focal Adhesion Kinase) small molecule inhibitor, targeting the issue of drug resistance in cancer treatment [2][4] - The company aims to address the common problem of drug resistance, which affects 80%-90% of cancer patients, by inhibiting FAK to disrupt cancer cells' defense mechanisms [4][5] Clinical Development - Ifebemtinib has shown promising results in clinical trials, particularly in combination with chemotherapy for platinum-resistant recurrent ovarian cancer, achieving an objective response rate (ORR) of 40.7% [5] - The drug has received breakthrough therapy designation from the FDA and the NMPA, with plans to submit a marketing application by the end of this year or early next year [5][6] Commercialization Strategy - Ying Shi Biotech has not yet achieved profitability, with operating losses of 174 million yuan, 143 million yuan, and 27.5 million yuan in 2023, 2024, and Q1 2025, respectively [6] - The company is building a sales team and collaborating with top hospitals to facilitate commercialization, while also exploring partnerships with established contract sales organizations (CSOs) [6][7] Competitive Landscape - The FAK inhibitor market is relatively new, with limited competition, as the first FAK inhibitor for ovarian cancer was only approved by the FDA in May 2023 [6][7] - The potential for Ifebemtinib in combination therapies may provide a competitive edge, as it can enhance the efficacy of existing treatments without direct competition [7][8]

Investment Rating - The report assigns a "Buy-A" investment rating to the company, with a 6-month target price of 93.12 HKD [4][6]. Core Insights - The company reported a revenue of 234 million RMB and a net profit loss of 591 million RMB for the first half of 2025. The sales of Aorebatin continued to grow, with a 93% increase in revenue from 113 million RMB in the first half of 2024 to 217 million RMB in the first half of 2025 [2]. - The approval of Lisaftoclax in China is expected to provide a new revenue source, with multiple clinical trials progressing rapidly [3]. - The company anticipates revenues of 520 million RMB, 2.78 billion RMB, and 1.57 billion RMB for 2025, 2026, and 2027, respectively, with net profits projected at -1.04 billion RMB, 700 million RMB, and -520 million RMB for the same years [4]. Financial Performance Summary - Revenue for 2023 was 221.98 million RMB, projected to increase to 980.65 million RMB in 2024, and then to 519.81 million RMB in 2025, followed by 2.78 billion RMB in 2026 and 1.57 billion RMB in 2027 [9]. - The net profit for 2023 was -926.79 million RMB, expected to improve to -405.40 million RMB in 2024, and then to -1.04 billion RMB in 2025, with a forecasted profit of 696.27 million RMB in 2026 and a loss of 520.65 million RMB in 2027 [13]. - The company’s gross margin is expected to remain around 90% from 2025 to 2034, indicating strong profitability potential [10]. Clinical Development Pipeline - Aorebatin is undergoing multiple clinical trials, including the POLARIS-3, POLARIS-2, and POLARIS-1 studies, which are progressing smoothly [2]. - Lisaftoclax has received NMPA approval for treating adult CLL/SLL patients who have undergone prior treatment, with several global clinical trials also in progress [3].

Core Viewpoint - Yasheng Pharmaceutical has transformed from an undervalued entity to a highly sought-after player in the pharmaceutical sector within six months, with its stock price doubling and a significant increase in sales of its core product, Nairike, by over 90% [1] Financial Performance - In the first half of 2025, Yasheng Pharmaceutical reported total revenue of RMB 234 million, a year-on-year decline of 71.6%, primarily due to a high base from significant overseas licensing milestone payments in H1 2024 [2] - Excluding one-time revenues, Nairike's sales reached RMB 217 million, reflecting a 93% year-on-year growth, driven by the inclusion of all approved indications in the national medical insurance catalog [2] - As of June 30, 2025, the company's cash and bank deposits amounted to RMB 1.661 billion, a 31.7% increase, largely due to approximately RMB 970 million raised from its IPO in the U.S. [2] Core Product Driving Growth - Nairike, Yasheng's first commercialized product, is the first third-generation BCR-ABL inhibitor approved in China, targeting patients with TKI resistance and T315I mutations [3] - Since January 2025, all approved indications for Nairike have been included in the national medical insurance drug list, with an annual reimbursement standard of RMB 174,500, enhancing patient affordability and accessibility [3] - By June 30, 2025, Nairike's sales in China increased from RMB 113 million in the previous year to RMB 217 million, with the number of hospitals carrying the product rising by 47% [3] Dual-Engine Commercialization Strategy - On July 10, 2025, Yasheng's second core product, Lishengtuo, was approved for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma [4] - Lishengtuo is the first domestically approved original Bcl-2 inhibitor in China and the second globally, indicating significant market potential [4] Rapid Commercialization of Lishengtuo - Following its approval, Yasheng quickly signed cooperation agreements with major pharmaceutical distribution companies to advance its commercialization efforts [5] - Within 15 days, the product was prescribed in over 40 hospitals across more than 30 cities, demonstrating swift market entry [6] Global R&D Pipeline - Yasheng is accelerating the global clinical development of its pipeline, with nine Phase III clinical studies underway, three of which have received FDA approval [7] - The Bcl-2 inhibitor APG-2575 is considered a promising candidate, targeting high-value indications such as CLL, AML, and MM [7] - Nairike has three global Phase III studies in progress, with one receiving FDA approval for use in Ph+ALL patients [7] Commercialization Strategy: From Single Product to Multi-curve Layout - Yasheng employs a hybrid model of "self-sales + cooperative licensing" to mitigate risks, optimizing its domestic coverage while sharing market and registration costs with partners abroad [9] - The company is diversifying its pipeline with IAP inhibitors and MDM2 inhibitors, aiming to reduce reliance on single products [10] - In the blood cancer sector, Yasheng aims to replicate the success of AbbVie's Venetoclax, which achieved significant sales through continuous indication expansion [11] Conclusion - The rapid growth of Nairike demonstrates a viable path for Yasheng in the commercialization of original domestic drugs, but future growth will depend on the clinical and registration pace of subsequent pipelines like APG-2575 and the effectiveness of its international expansion strategy [12]

Group 1 - U.S. stocks experienced mixed performance, with the Dow Jones index declining over 200 points on Monday [1] - Keurig Dr Pepper Inc. shares fell sharply by 7.8% to $32.38 following the announcement of its acquisition of JDE Peet's [1] - Valneva SE shares dropped 21% to $9.19 after the FDA suspended the license for IXCHIQ [3] Group 2 - DeFi Development Corp. saw its shares dip 18% to $16.51 after announcing a $125 million offering of 4.2 million shares at $12.50 per share [3] - Venu Holding Corporation's shares fell 13.3% to $15.56 after announcing an offering of 1.7 million shares [3] - Axogen, Inc. shares declined 10.2% to $14.60 due to an FDA Major Amendment designation delaying the Avance Nerve Graft decision to December 5, 2025 [3]